| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-77461SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56694SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-27293SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-33074 | |||
| IHC-Prediluted | NBP2-44976 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-504-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56583SS | |||
| Azide and BSA Free | NBP2-80872 | |||
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody - BSA Free [NBP1-77461] - RUNX2/CBFA1 Antibody [NBP1-77461] - Vascularization of mineralized cell-laden collagen and interaction with prostate cancer cells. HUVECs formed endothelial networks that were supported by SMA-expressing hMSCs (scale bar: 50m) and were also positive for CD31 (scale bar: 400m). The remainder of hMSCs expressed RUNX2 as a marker for osteogenic differentiation (scale bar: 50m). Rapid fabrication of vascularized and innervated cell-laden bone models with biomimetic intrafibrillar collagen mineralization. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31388010/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunohistochemistry-Paraffin-NBP1-77461-img0009.jpg "Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody - BSA Free [NBP1-77461] - RUNX2/CBFA1 Antibody [NBP1-77461] - Vascularization of mineralized cell-laden collagen and interaction with prostate cancer cells. HUVECs formed endothelial networks that were supported by SMA-expressing hMSCs (scale bar: 50m) and were also positive for CD31 (scale bar: 400m). The remainder of hMSCs expressed RUNX2 as a marker for osteogenic differentiation (scale bar: 50m). Rapid fabrication of vascularized and innervated cell-laden bone models with biomimetic intrafibrillar collagen mineralization. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31388010/) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: RUNX2/CBFA1 Antibody [NBP1-77461] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with RUNX2/CBFA1 Antibody (NBP1-77461) at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-77461-img0010.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody - BSA Free [NBP1-77461] - RUNX2/CBFA1 Antibody [NBP1-77461] - Characterization of TLC cultured in chondrogenic pellets. Gene expression of TLC cultured four weeks in chondrogenic pellets or in cell monolayer in control medium: levels of expression of osteoblast markers (1), chondrocyte markers (2) and tenocyte markers (3) (N = 3) assessed by qPCR.* =0.05. Rotator Cuff Tenocytes Differentiate into Hypertrophic Chondrocyte-Like Cells to Produce Calcium Deposits in an Alkaline Phosphatase-Dependent Manner. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31561454/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunohistochemistry-Paraffin-NBP1-77461-img0008.jpg)
![Immunohistochemistry: RUNX2/CBFA1 Antibody [NBP1-77461] - Staining of RUNX2 in mouse prostate using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunohistochemistry-NBP1-77461-img0006.jpg)
![Immunohistochemistry: RUNX2/CBFA1 Antibody - BSA Free [NBP1-77461] - Histological characterization of rotator cuff calcifications (N = 5). (A) Calcific deposits assessed by micro-computed tomography. (B) HE (hematoxylin & eosin) staining of decalcified samples (1 image for each patient). (C) Von Kossa staining on not decalcified samples & characterization of the fibrocartilaginous area with alcian blue staining, SOFG (Safranin O/Fast Green) staining, & immunohistochemical staining for COL2 (brown) with Gill hematoxylin counterstain. (D,E) Representative immunohistochemical staining for ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1), TNAP (tissue non-specific alkaline phosphatase), Runx2, Sox9, Col10 & CD31 (brown). TF: tendon fibers; CD: calcium deposits, FM: fibrocartilaginous metaplasia; OM: osseous metaplasia; CT: connective tissue; V: vessels. Scale bar = 200 µM. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31561454), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77461_rabbit-polyclonal-runx2-cbfa1-antibody-310202416154628.jpg)
![Western Blot: FOXO3 Antibody [NBP2-16521] - FoxO3 expression in nuclear and cytosolic fraction of human breast cancer cell line MDA-MB-231. Image from verified customer review.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NBP2-16521-img0021.jpg "Western Blot: FOXO3 Antibody [NBP2-16521] - FoxO3 expression in nuclear and cytosolic fraction of human breast cancer cell line MDA-MB-231. Image from verified customer review.")
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Mouse duodenum. FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:2000. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-Paraffin-NBP2-16521-img0028.jpg)
![<b>Genetic Strategies Validation. </b>Chromatin Immunoprecipitation (ChIP): FOXO3 Antibody [NBP2-16521] - (D) ChIP assay for LMOD1 and EGFR (as a positive control region) in HCASMC chromatin lysates immunoprecipitated with antibodies to FOXO3 or a negative control rabbit IgG. n = 3. (E) Allele specific ChIP (haploChIP) for FOXO3 protein in DNA derived from cultured HCASMC ChIP experiments. DNA from cell line homozygous for the ancestral allele was used as a positive control and arbitrarily set to 1. Values represent mean +/- standard deviation of triplicates. Similar results were observed from n = 4 independent lines for each genotype. (F) Quantitative RT-PCR analysis of LMOD1 in HCASMCs following knock down of endogenous FOXO3 (F) or overexpression of FOXO3 (G). The results were reproduced in n = 3 independent experiments. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pgen.1007755) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Chromatin-Immunoprecipitation-ChIP-NBP2-16521-img0030.jpg)
![Western Blot: FOXO3 Antibody [NBP2-16521] - 50 ug of mouse brain whole cell lysate). Antibody at 1:500.](http://images.novusbio.com/fullsize/FOXO3A-Antibody-Western-Blot-NBP2-16521-img0002.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Huh-7 xenograft, using FOXO3A antibody at 1:500 dilution. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.](http://images.novusbio.com/fullsize/FOXO3A-Antibody-Immunohistochemistry-Paraffin-NBP2-16521-img0003.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Rat colon. FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:2000.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-Paraffin-NBP2-16521-img0024.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Rat brain. FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:2000.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-Paraffin-NBP2-16521-img0026.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Mouse brain. FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:2000. Antigen Retrieval: Citrate buffer, pH 6.0, 15 minutes.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-Paraffin-Negative-NBP2-16521-img0027.jpg)
![Immunoprecipitation: FOXO3 Antibody [NBP2-16521] - Jurkat whole cell lysate/extract A. Control with 2 ug of preimmune rabbit IgG B. Immunoprecipitation of FOXO3A protein by 2 ug of FOXO3A antibody 5% SDS-PAGE The immunoprecipitated FOXO3A protein was detected by FOXO3A antibody diluted at 1:1000. EasyBlot anti-rabbit IgG was used as a secondary reagent.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunoprecipitation-NBP2-16521-img0029.jpg)
![Western Blot: FOXO3 Antibody [NBP2-16521] - LMOD1 expression is mediated by PDGF-BB-FOXO3 signaling cascade.(A) UCSC Browser screenshot of the LMOD1 CAD locus at chromosome 1q32.1 highlighting the candidate causal variant, rs34091558, overlapping ATAC-seq open chromatin & RNA-seq tracks in HCASMCs treated with PDGF-BB (n = 2 biological replicates). Genomic coordinates refer to hg19 assembly. Quantitative RT-PCR (B) & Western blotting (C) data revealing PDGF-BB & phosphorylated-FOXO3 (P-FOXO3) mediated LMOD1 expression. (D) Co-expression microarray analysis performed in a cohort of carotid atherosclerotic plaques (n = 127) indicating that LMOD1 & FOXO3 are positively correlated in arterial tissues. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30444878), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-310202415345315.jpg)
![Immunoprecipitation: FOXO3 Antibody [NBP2-16521] - Chemotherapy-induced A2BR expression promotes FOXO3 binding on pluripotency factor genes through decreased H3K27me3 & increased H3K27ac chromatin marks. A & B, MDA-MB-231 NTC or A2BR knockdown subclones were transfected with pLX304 (empty vector, EV) or pLX304 encoding A2BR. Cells were treated with vehicle (V) or 10 nM paclitaxel (P) for 72 h & chromatin immunoprecipitation (ChIP) was performed with antibody against FOXO3. Primers flanking the FOXO3 binding site in the NANOG, SOX2 & KLF4 gene (A) were used for qPCR (B; mean ± SEM; n = 3); **p Sample: Paraffin-embedded human glioblastoma.FOXO3A stained by FOXO3A antibody [C3], C-term (NBP2-16521) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-immunohistochemistry-paraffin-2611202518191319.jpg)
![<b>Genetic Strategies Validation. </b>Non-transfected (-) and transfected (+) C2C12 whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with FOXO3A antibody [C3], C-term (NBP2-16521) diluted at 1:500. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-western-blot-2611202518303821.jpg)
![FOXO3A antibody [C3], C-term detects FOXO3A protein at nucleus by immunofluorescent analysis.Sample: HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: FOXO3A stained by FOXO3A antibody [C3], C-term (NBP2-16521) diluted at 1:1000.Blue: Hoechst 33342 staining.Scale bar= 10 um.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-immunocytochemistry-immunofluorescence-261120251845408.jpg)
![Various whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with FOXO3A antibody [C3], C-term (NBP2-16521) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-western-blot-261120251824390.jpg)
![FOXO3A antibody [C3], C-term detects FOXO3A protein at nucleus by immunohistochemical analysis.Sample: Paraffin-embedded mouse testis.FOXO3A stained by FOXO3A antibody [C3], C-term (NBP2-16521) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-immunohistochemistry-paraffin-2611202518441020.jpg)
![Immunoprecipitation: TRF-2 Antibody [NB100-56694] - Analysis of TRF-2 in HL60 cells. Lane 1. IP (mouse anti-TRF2). Lane 2. IP with control mouse IgG. Lane 3 IP with goat anti-TRF2. Lane 4. IP with pre-immune goat Ig. Lanes 1-4. WB. TRF2 is detected as a ~ 66 kD protein.](http://images.novusbio.com/fullsize/TRF-2-Antibody-Immunoprecipitation-NB100-56694-img0006.jpg "Immunoprecipitation: TRF-2 Antibody [NB100-56694] - Analysis of TRF-2 in HL60 cells. Lane 1. IP (mouse anti-TRF2). Lane 2. IP with control mouse IgG. Lane 3 IP with goat anti-TRF2. Lane 4. IP with pre-immune goat Ig. Lanes 1-4. WB. TRF2 is detected as a ~ 66 kD protein.")
![Immunohistochemistry-Paraffin: TRF-2 Antibody [NB100-56694] - Analysis of Human Tonsil using TRF-2 antibody.](http://images.novusbio.com/fullsize/TRF-2-Antibody-Immunohistochemistry-Paraffin-NB100-56694-img0005.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: TRF-2 Antibody [NB100-56694] - U2OS cells were transduced with a lentiviral vector coding for a Dox inducible control shRNA (shCtrl) or a shRNA against TRF-2 (shTRF2) and selected with puromycin +/- Dox for a week. A) Western blot analysis of TRF-2 expression one week post selection. Membranes were also probed with anti-tubulin antibodies to show the input material loaded. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TRF-2-Antibody-Knockdown-Validated-NB100-56694-img0007.jpg)
![<b>Genetic Strategies Validation. </b>Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - U2OS cells were transduced with a lentiviral vector coding for a Dox inducible control shRNA (shCtrl) or a shRNA against TRF-2 (shTRF2) and selected with puromycin +/- Dox for a week. One week post selection, +Dox cells were infected with HHV-6A for 48h and processed for IFA using anti-TRF-2 (green) and anti-IE2 (red). Cells with IE2 in punctate form and cells with large patchy IE2, likely to represent VRC, are shown. Nuclei are outlined by dashed lines. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TRF-2-Antibody-Knockdown-Validated-NB100-56694-img0008.jpg)
![Western Blot: TRF-2 Antibody [NB100-56694] - TRF2 knockdown affect HHV-6A/B chromosomal integration.A) U2OS cells were transduced with lentiviral vectors expressing a scrambles shRNA (shCtrl) or a shTRF2. After a week of selection, cells were monitored for TRF2 expression by western blot. B) After a week of selection, shCtrl & shTRF2 treated cells were infected with HHV-6A or HHV-6B. After 30 days, DNA was isolated & the relative frequency of integration, relative to shCtrl set at 100%, estimated by ddPCR. *p<0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-310202415345328.jpg)
![Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - TRF2 expression in HHV-6A-infected U2OS cells.U2OS cells were infected with HHV-6A & analyzed for TRF2 & IE2 expression at 24h, 48h & 72h post-infection by dual color immunofluorescence. A) Representative immunofluorescence of TRF2 & IE2 expression in bystander & IE2 expressing cells at 24, 48h & 72h post infection. B) Mean relative TRF2 expression ± SD in uninfected (blue), IE2- (green-uninfected bystander) or IE2+ (red-infected) cells at 24h, 48h & 72h post infection. Each symbol represents the relative TRF2 expression from a single nucleus. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-310202415304273.jpg)
![Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - Binding of TRF2 to viral DNA during HHV-6A/B infection.A) Schematic representation of the HHV-6A/B genome. The DR6 probe used for hybridization is shown in red. Uninfected & HHV-6A-infected HSB-2 cells (B-D) or uninfected & HHV-6B-infectd Molt-3 cells (E-F) were analyzed for TRF2 binding to viral DNA using ChIP. The input was hybridized with Alu probe to assess quantity of starting material. Anti-IgG (negative control), anti-PolII (positive control) or TRF2 antibodies were used for immunoprecipitation. B) QPCR detection of GAPDH DNA following ChIP. Results are expressed as fold increase over control IgG. C & E) Eluted DNA was hybridized with 32P-labeled Alu, telomeric (TTAGGG)3 or HHV-6A (DR6) probes. After hybridization the membranes were washed & exposed to X-ray films. D & F) Densitometric analysis of relative binding of TRF2 to telomeric & viral DNA. Results of one experiment representative of three are presented & are expressed as signal after normalization to input. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-3102024155376.jpg)
![Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - TRF2 is required for IE2 localization with telomeres.U2OS cells were transduced with a lentiviral vector coding for a Dox inducible control shRNA (shCtrl) or a shRNA against TRF2 (shTRF2) & selected with puromycin +/- Dox for a week. A) Western blot analysis of TRF2 expression one week post selection. Membranes were also probed with anti-tubulin antibodies to show the input material loaded. B) One week post selection, +Dox cells were infected with HHV-6A for 48h & processed for IFA using anti-TRF2 (green) & anti-IE2 (red). Cells with IE2 in punctate form & cells with large patchy IE2, likely to represent VRC, are shown. Nuclei are outlined by dashed lines. C) The percentage of HHV-6A infected cells (from B) was estimated after counting a minimum of 700 cells & scoring the IE2+ ones. Results are expressed as mean %IE2+ cells ± SD. D) Mean percentage ± SD of IE2 localizing with telomeres in the presence (shCtrl +Dox) & absence (shTRF2 +Dox) of TRF2. Each dot represents the % of IE2 foci localizing with telomeres in one nucleus. ****p<0.0001. E) IF-FISH confocal images of shCtrl (+Dox) & shTRF2 (+Dox) cells analyzed for TRF2 (green), IE2 (red) & telomeres (cyan). Nuclei are outlined by dashed circles. Examples of IE2 localizing with telomeres (top row) or not found with telomeres (bottom row) are highlighted by the dashed polygons. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-31020241612657.jpg)
![Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - Binding of TRF2 to viral DNA during HHV-6A/B infection.A) Schematic representation of the HHV-6A/B genome. The DR6 probe used for hybridization is shown in red. Uninfected & HHV-6A-infected HSB-2 cells (B-D) or uninfected & HHV-6B-infectd Molt-3 cells (E-F) were analyzed for TRF2 binding to viral DNA using ChIP. The input was hybridized with Alu probe to assess quantity of starting material. Anti-IgG (negative control), anti-PolII (positive control) or TRF2 antibodies were used for immunoprecipitation. B) QPCR detection of GAPDH DNA following ChIP. Results are expressed as fold increase over control IgG. C & E) Eluted DNA was hybridized with 32P-labeled Alu, telomeric (TTAGGG)3 or HHV-6A (DR6) probes. After hybridization the membranes were washed & exposed to X-ray films. D & F) Densitometric analysis of relative binding of TRF2 to telomeric & viral DNA. Results of one experiment representative of three are presented & are expressed as signal after normalization to input. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-310202415523926.jpg)
![Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - A) A stick diagram of the IE2 protein with various domains identified is presented. B) Colocalization of HHV-6A IE2 protein with telomeres in the absence of viral DNA. U2OS cells were transfected with an empty vector, with IE2 expression vector or with IE2 delta 1290–1500 expression vector. Forty-eight hours later cells were processed for dual color immunofluorescence. Telomeres were labeled in cyan & IE2 in red. Nuclei are outlined by dashed lines. Examples of IE2 colocalizing with telomeres are presented in a 3D view (white arrows). C) The graph represents the mean ± SD % of WT IE2 & delta 1290–1500 IE2 localizing with telomeres. D) Lack of colocalization between HHV-6A p41 & telomeres in uninfected cells. U2OS cells were transfected with an empty vector or with a p41 expression vector. Forty-eight hours later cells were processed for dual color immunofluorescence. TRF2 was labeled green, p41 in red & nuclei outlined by a dashed line. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-310202415541930.jpg)
![Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - Colocalization of shelterin complex proteins & HHV-6A IE2 protein at VRC & cellular telomeres.A) U2OS cells were mock-infected or infected with HHV-6A for 48h after which cells were processed for IF-FISH. Telomeres were labeled in magenta, TRF2 in green & IE2 in red. The panels in the middle row show images of cells with IE2 patches overlapping with large, diffuse TRF2 & telomeric staining (rectangles). The panels in the third row represent infected cells with punctate IE2 pattern colocalizing with TRF2 & telomeres (dashed squares). The colocalization of IE2, TRF2 & telomeres are shown in both 2D & 3D images. B) Uninfected & HHV-6A-infected U2OS cells were transfected with an empty vector, a myc-tagged-TRF1 expression vector. Forty-eight hours later cells were processed for IF-FISH. TRF1 was labeled in green & IE2 in red. Nuclei were stained with DAPI. Images on the far right show 2D colocalization of TRF1 with IE2. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-31020241612621.jpg)
![Western Blot: Snail Antibody [NBP2-27293] - Cisplatin-resistant gastric cancer cells exhibit an EMT-like phenotypic change. Epithelial marker E-cadherin, ZO1 and EMT-related transcription factor Snail were examined by Western blot. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep20502), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Snail-Antibody-Western-Blot-NBP2-27293-img0005.jpg "Western Blot: Snail Antibody [NBP2-27293] - Cisplatin-resistant gastric cancer cells exhibit an EMT-like phenotypic change. Epithelial marker E-cadherin, ZO1 and EMT-related transcription factor Snail were examined by Western blot. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep20502), licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: Snail Antibody [NBP2-27293] - Analysis of a FFPE tissue section of mouse placenta using 1:200 dilution of SNAIL antibody. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/Snail-Antibody-Immunohistochemistry-Paraffin-NBP2-27293-img0007.jpg)
![Western Blot: Snail Antibody [NBP2-27293] - HER2 is overexpressed and both Herceptin incubation and siRNAs against HER2 reversed the EMT in cisplatin-resistant gastric cancer cells. Effects of Herceptin on levels of ZO1 and Snail. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep20502), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Snail-Antibody-Western-Blot-NBP2-27293-img0006.jpg)
![Immunohistochemistry-Paraffin: Snail Antibody [NBP2-27293] - Analysis of in FFPE human kidney tissue using this antibody at 5 ug/mL.](http://images.novusbio.com/fullsize/Snail-Antibody-Immunohistochemistry-Paraffin-NBP2-27293-img0004.jpg)
![Simple Western: Snail Antibody [NBP2-27293] - Image shows a specific band for SNAIL in 0.5 mg/mL of MCF-7 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Snail-Antibody-Simple-Western-NBP2-27293-img0002.jpg)
![Western Blot: Snail Antibody - BSA Free [NBP2-27293] - SiRNAs against HER2 could abrogate the EMT phenotype & cell invasiveness in cisplatin-resistant gastric cancer cells.(A) Validation of silencing efficiency of HER2. Cells were transiently transfected with 50 nM HER2-specific siRNAs #1-#3 or a control siRNA for 48 h. (B) Knock-down of HER2 abrogated EMT morphology. Cells were transiently transfected with 50 nM specific siRNAs targeting HER2 for 48 h, Representative images of cellular morphology were shown. (C) Knock-down of HER2 abolished EMT phenotype. Cells were treated as in Fig. 4B. FITC-phalloidin staining of F-actin were performed & representative images were shown. (D) Effects of HER2 knock-down on the levels of ZO1 & Snail. (E) Effects of HER2 knock-down on cell migration. Representative images of transwell cell migration assay were shown. (F) Summary of Fig. 4E. Values represented the mean ± SD from three independent experiments with triplicate samples. *P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26846307), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-27293_rabbit-polyclonal-snail-antibody-310202416114759.jpg)
![Western Blot: Snail Antibody - BSA Free [NBP2-27293] - HER2 is overexpressed & both Herceptin incubation & siRNAs against HER2 reversed the EMT in cisplatin-resistant gastric cancer cells.(A) Western blot of HER2 in MGC803/DDP & AGS/DDP cell lines, & parental MGC803 & AGS cells. GAPDH was used as loading control. (B) Relative amplification of HER2 in parental & cisplatin-resistant cells. Results were presented as the mean ± SD of two independent experiments, *P < 0.05 compared with parental cells. (C) Herceptin incubation abrogated EMT morphology in MGC803/DDP cells. Representative images of cellular morphology of MGC803/DDP cells, plus parental MGC803 cells treated with Herceptin for 24 h were shown. Hercep represents Herceptin. (D) Herceptin incubation reversed EMT morphology in MGC803/DDP cells. Representative images of FITC-phalloidin staining of F-actin after 100 μg/ml Herceptin treatment for 24 h were shown. (E) Effects of Herceptin on levels of ZO1 & Snail. (F) CP724714 treatment abolished EMT-like cell morphology. Cells were incubated with 10 μM CP724714 for 24 h. Representative images of cellular morphology of were captured. (G) CP724714 treatment abrogated EMT-like cell morphology. Cells were treated as in Fig. 4F, FITC-phalloidin staining of F-actin was performed & typical images were shown. (H) Effects of CP724714 on ZO1 & Snail. (I) CP724714 inhibited the increased cell migration in cisplatin-resistant gastric cancer cells. Representative images were presented here. (J) CP724714 inhibited the increased cell migration in cisplatin-resistant gastric cancer cells. Values represented the mean ± SD from three independent experiments with triplicate samples. *P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26846307), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-27293_rabbit-polyclonal-snail-antibody-310202416113529.jpg)
![Immunocytochemistry/Immunofluorescence: MafA Antibody [NBP1-00121] - Analysis of MafA in 8-week old mouse pancretic cryosection using anti-MafA antibody (red). Image from verified customer review.](http://images.novusbio.com/fullsize/MafA-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-00121-img0003.jpg "Immunocytochemistry/Immunofluorescence: MafA Antibody [NBP1-00121] - Analysis of MafA in 8-week old mouse pancretic cryosection using anti-MafA antibody (red). Image from verified customer review.")
![Immunohistochemistry-Paraffin: MafA Antibody [NBP1-00121] - Section of mouse pancreatic islet. Antibody: Affinity purified rabbit anti-MafA (Cat. No. NBP1-00121) used at a dilution of 1:250.](http://images.novusbio.com/fullsize/MafA-Antibody-Immunohistochemistry-Paraffin-NBP1-00121-img0001.jpg)
![Western Blot: p53 Antibody [NB200-171] - Whole cell lysate (5, 15 and 50 ug) from 293T cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit antiP53 antibody used for WB at0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/p53-Antibody-Western-Blot-NB200-171-img0076.jpg "Western Blot: p53 Antibody [NB200-171] - Whole cell lysate (5, 15 and 50 ug) from 293T cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit antiP53 antibody used for WB at0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.")
![Immunohistochemistry-Paraffin: p53 Antibody [NB200-171] - FFPE section of human lung cancer Antibody: Affinity purified rabbit anti- p53 used at 1:5,000 (0.2ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/p53-Antibody-Immunohistochemistry-Paraffin-NB200-171-img0075.jpg)
![Flow Cytometry: p53 Antibody [NB200-171] - p53 in Jurkat Cells, fixed in 1.5% PFA, and permeabilized in 90% Methanol. 1 million cells were stained with 1.5 ug anti-KLH IgG control or anti-p53 NB200-171 and secondary FITC-conjugated goat anti-rabbit (in a 150ul reaction). Black- anti-KLH control IgG; Red- anti-HDMX.](http://images.novusbio.com/fullsize/p53-Antibody-Flow-Cytometry-NB200-171-img0002.jpg)
![Chromatin Immunoprecipitation Sequencing: p53 Antibody [NB200-171] - Chromatin from MCF7 was immunoprecipitated with anti-p53 antibody and analyzed by DNA sequencing. The figure illustrates the peak distribution of p53 binding within a 250 Kb region of chromosome 6 as detected using anti-p53. ChIP-seq validation performed by Active Motif, Carlsbad, CA.](http://images.novusbio.com/fullsize/p53-Antibody-Chromatin-Immunoprecipitation-Sequencing-NB200-171-img0073.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: p53 Antibody [NB200-171] - Whole cell lysate (100 ug) from 293T cells that were treated with an siRNA for p53 (+) or mock treated (-). Antibody used at the indicated concentrations.](http://images.novusbio.com/fullsize/p53-Antibody-Western-Blot-NB200-171-img0003.jpg)
![Flow Cytometry: p53 Antibody [NB200-171] - Baseline p53 expression in human lymphocytes. Image from verified customer review.](http://images.novusbio.com/fullsize/p53-Antibody-Flow-Cytometry-NB200-171-img0004.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: p53 Antibody [NB200-171] - Detection of human P53 by western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HEK293T cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-P53 antibody NB200-171 used for IP at 3 ug per reaction. P53 was also immunoprecipitated by rabbit anti-P53 antibody NB100-2204. For blotting immunoprecipitated P53, NB200-171 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/p53-Antibody-Immunoprecipitation-NB200-171-img0077.jpg)
![Western Blot: p53 Antibody (BP53-12) [NBP2-29453] - Western Blot Analysis of human HeLa cell lysate using p53 Antibody (BP53-12).](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Western-Blot-NBP2-29453-img0010.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (BP53-12) [NBP2-29453] - p53 was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using a 1 ug/mL mouse anti-p53 monoclonal (NBP2-29453, Novus Biologicals) for 1 hour at room temperature followed by the appropriate HRP polymer reagent, anti-mouse IgG VisUCyte HRP polymer (VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue).](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Immunohistochemistry-Paraffin-NBP2-29453-img0008.jpg)
![Western Blot: p53 Antibody (BP53-12) [NBP2-29453] - Analysis of p53 1) A431 2) MCF7 and 3) HEK293 lysate probed with p53 antibody at 1 ug/ml. goat anti-mouse Ig HRP secondary antibody and PicoTect ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Western-Blot-NBP2-29453-img0001.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (BP53-12) [NBP2-29453] - Formalin-paraffin human colon carcinoma stained with p53 Ab (BP53-12).](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Immunohistochemistry-Paraffin-NBP2-29453-img0003.jpg)
![Simple Western: p53 Antibody (BP53-12) [NBP2-29453] - Simple Western lane view shows a specific band for p53 in 0.2 mg/ml of MDA-MB-231 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Simple-Western-NBP2-29453-img0004.jpg)
![Simple Western: p53 Antibody (BP53-12) [NBP2-29453] - Electropherogram image of the corresponding Simple western lane view. p53 antibody was used at 10 ug/ml dilution on MDA-MB-231 lysate(s) respectively.](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Simple-Western-NBP2-29453-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: NFATC2/NFAT1 Antibody (25A10.D6.D2) [NB300-504] - Analysis of NFATc2 (green) in HeLa cells. Formalin fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 10 minutes at room temperature and blocked with 1% Blocker BSA for 15 minutes at room temperature. Cells were left untreated (left panel) or treated with 1uM staurosporine (right panel) for 3 hours and probed with a NFATc2 monoclonal antibody, at a dilution of 1:100 for at least 1 hour at room temperature, washed with PBS, and incubated with DyLight 488 goat anti-mouse IgG secondary antibody at a dilution of 1:400 for 30 minutes at room temperature. F-Actin (red) was stained with DyLight 554 Phalloidin and nuclei (blue) were stained with Hoechst 33342 dye.](http://images.novusbio.com/fullsize/NFATC2-NFAT1-Antibody-25A10-D6-D2-Immunocytochemistry-Immunofluorescence-NB300-504-img0010.jpg "Immunocytochemistry/Immunofluorescence: NFATC2/NFAT1 Antibody (25A10.D6.D2) [NB300-504] - Analysis of NFATc2 (green) in HeLa cells. Formalin fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 10 minutes at room temperature and blocked with 1% Blocker BSA for 15 minutes at room temperature. Cells were left untreated (left panel) or treated with 1uM staurosporine (right panel) for 3 hours and probed with a NFATc2 monoclonal antibody, at a dilution of 1:100 for at least 1 hour at room temperature, washed with PBS, and incubated with DyLight 488 goat anti-mouse IgG secondary antibody at a dilution of 1:400 for 30 minutes at room temperature. F-Actin (red) was stained with DyLight 554 Phalloidin and nuclei (blue) were stained with Hoechst 33342 dye.")
![Immunohistochemistry-Paraffin: NFATC2/NFAT1 Antibody (25A10.D6.D2) [NB300-504] - Both normal and cancer biopsies of deparaffinized Human spleen tissue tissues.](http://images.novusbio.com/fullsize/NFATC2-NFAT1-Antibody-25A10-D6-D2-Immunohistochemistry-Paraffin-NB300-504-img0012.jpg)
![Chromatin Immunoprecipitation: NFATC2/NFAT1 Antibody (25A10.D6.D2) [NB300-504] - IP performed using Matrix ChIP assay with 1.0ul/100ul well of NFATc2 mab. Chromatin aliquots from ~1x10^5 cells used per ChIP pull-down. Quantitative PCR data done x4 using 1ul of eluted DNA in 2ul SYBR real-time PCR reactions containing primers to amplify exon-1 or exon-28 of LAMC1. PCR calibration curves generated per primer pair from a series of sheared total genomic DNA. ChIP presented relative to the total amount of input chromatin. Results represent mean +/- SEM for 3 experiments. Representation of rat LAMC1 locus shown above data where boxes represent exons (black = translated regions, white = untranslated regions); zigzag line represents an intron, & straight line represents upstream sequence. Regions amplified by LAMC1 primers are represented by black bars. Data courtesy of the Innovators Program.](http://images.novusbio.com/fullsize/NFATC2-NFAT1-Antibody-25A10-D6-D2-Chromatin-Immunoprecipitation-NB300-504-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: NFATC2/NFAT1 Antibody (25A10.D6.D2) [NB300-504] - Analysis of NFATc2 using NFATc2 Monoclonal Antibody (25A10.D6.D2) shows staining in Hela Cells. NFATc2 (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with an antibody recognizing NFATc2 at a dilution of 1:20 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/NFATC2-NFAT1-Antibody-25A10-D6-D2-Immunocytochemistry-Immunofluorescence-NB300-504-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: NFATC2/NFAT1 Antibody (25A10.D6.D2) [NB300-504] - Analysis of NFATc2 using NFATc2 Monoclonal Antibody (25A10.D6.D2) shows staining in MCF-7 Cells. NFATc2 (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with an antibody recognizing NFATc2 at a dilution of 1:20 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/NFATC2-NFAT1-Antibody-25A10-D6-D2-Immunocytochemistry-Immunofluorescence-NB300-504-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: NFATC2/NFAT1 Antibody (25A10.D6.D2) [NB300-504] - Analysis of NFATc2 using NFATc2 Monoclonal Antibody (25A10.D6.D2) shows staining in U251 Cells. NFATc2 (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with an antibody recognizing NFATc2 at a dilution of 1:20 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/NFATC2-NFAT1-Antibody-25A10-D6-D2-Immunocytochemistry-Immunofluorescence-NB300-504-img0008.jpg)
![Immunohistochemistry-Paraffin: NFATC2/NFAT1 Antibody (25A10.D6.D2) [NB300-504] - Cancer biopsies of deparaffinized Human colon carcinoma tissues.](http://images.novusbio.com/fullsize/NFATC2-NFAT1-Antibody-25A10-D6-D2-Immunohistochemistry-Paraffin-NB300-504-img0004.jpg)
![Immunohistochemistry-Paraffin: NFATC2/NFAT1 Antibody (25A10.D6.D2) [NB300-504] - Both normal and cancer biopsies of deparaffinized Human tonsil tissues.](http://images.novusbio.com/fullsize/NFATC2-NFAT1-Antibody-25A10-D6-D2-Immunohistochemistry-Paraffin-NB300-504-img0011.jpg)
![Western Blot: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - Analysis of p50 in HeLa lysate in the A) absence and B) presence of immunizing peptide using p50 antibody at 5 ug/ml.](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Western-Blot-NB100-56583-img0004.jpg "Western Blot: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - Analysis of p50 in HeLa lysate in the A) absence and B) presence of immunizing peptide using p50 antibody at 5 ug/ml.")
![Immunohistochemistry-Paraffin: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - IHC-P of rabbit aorta using NB100-56583. Secondary antibody: anti-mouse histofine ( Nisherei Bioscience Inc. ref: 414131F). Development: DAB (Dako ref: K346811-2) and counterstained with Hematoxylin. Submitted via verified customer review](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Immunohistochemistry-Paraffin-NB100-56583-img0009.jpg)
![Flow Cytometry: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - An intracellular stain was performed on U937 cells with NFkB p105/p50 [2J10D7] Antibody NB100-56583C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 650.](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Flow-Cytometry-NB100-56583-img0008.jpg)
![Immunohistochemistry-Paraffin: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - analysis of human breast tumor tissue using an isotype control antibody (top) and p50 antibody (bottom) at 5 ug/ml.](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Immunohistochemistry-Paraffin-NB100-56583-img0003.jpg)
![Flow Cytometry: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - An intracellular stain was performed on Jurkat cells with NFkB p105/p50 Antibody (2J10D7) NB100-56583C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes. Both antibodies were conjugated to Dylight 650.](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Flow-Cytometry-NB100-56583-img0005.jpg)
![Flow Cytometry: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - An intracellular stain was performed on HeLa cells with NFkB p105/p50 Antibody (2J10D7) NB100-56583C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes. Both antibodies were conjugated to Dylight 650.](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Flow-Cytometry-NB100-56583-img0006.jpg)
![Flow Cytometry: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - An intracellular stain was performed on U2-OS cells with NFkB p105/p50 [2J10D7] Antibody NB100-56583C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 650.](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Flow-Cytometry-NB100-56583-img0007.jpg)
![Immunohistochemistry-Paraffin: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - Analysis of a FFPE tissue section of human lymph node using 1:200 dilution of NFkB p105/p50 (2J10D7) antibody. The staining was developed using HRP labeled anti-mouse secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/antibody/nb100-56583_mouse-monoclonal-nfkb-p105-p50-antibody-2j10d7-imgenex-img-5812a-2210202585646.jpg)
![Western Blot: FoxP3 Antibody [NB600-242] - (1 ug/mL) staining of Human Muscle (A), (2 ug/mL) MOLT4 (B) and (1 ug/mL) negative control Pancreas (C) lysate (35 ug protein in RIPA buffer). Detected by chemiluminescence.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Western-Blot-NB600-242-img0010.jpg "Western Blot: FoxP3 Antibody [NB600-242] - (1 ug/mL) staining of Human Muscle (A), (2 ug/mL) MOLT4 (B) and (1 ug/mL) negative control Pancreas (C) lysate (35 ug protein in RIPA buffer). Detected by chemiluminescence.")
![Immunocytochemistry: FoxP3 Antibody [NB600-242] - (Treg) human blood cells gathered by cytospin and detected by FITC (A) and in phase contrast (B).](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunocytochemistry-Immunofluorescence-NB600-242-img0008.jpg)
![Immunohistochemistry: FoxP3 Antibody [NB600-242] - (8ug/ml) staining of paraffin embedded Human Spleen. Heat induced antigen retrieval with citrate buffer Ph 6, HRP-staining.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunohistochemistry-NB600-242-img0012.jpg)
![Flow Cytometry: FoxP3 Antibody [NB600-242] - Analysis of paraformaldehyde fixed Jurkat cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (4 ug/mL). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Flow-Cytometry-NB600-242-img0009.jpg)
![Immunofluorescence: FoxP3 Antibody [NB600-242] - Paraformaldehyde fixed U2OS cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (4 ug/mL), showing strong localization to nucleoplasm. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (4 ug/mL).](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunocytochemistry-Immunofluorescence-NB600-242-img0011.jpg)
![Control: FoxP3 Antibody [NB600-242] - Negative Control showing staining of paraffin embedded Human Spleen, with no primary antibody.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Control-NB600-242-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: STAT3 Antibody [NB100-799] - Immunofluorescence analysis of paraformaldehyde fixed HeLa cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing cytoplasmic and weak nuclear staining. Actin filaments were stained with phalloidin (red) and the nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL).](http://images.novusbio.com/fullsize/STAT3-Antibody-Immunocytochemistry-Immunofluorescence-NB100-799-img0005.jpg "Immunocytochemistry/Immunofluorescence: STAT3 Antibody [NB100-799] - Immunofluorescence analysis of paraformaldehyde fixed HeLa cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing cytoplasmic and weak nuclear staining. Actin filaments were stained with phalloidin (red) and the nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL).")
![Immunohistochemistry-Paraffin: STAT3 Antibody [NB100-799] - Immunofluorescence analysis of paraformaldehyde fixed A431 cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing nuclear and cytoplasmic staining. Actin filaments were stained with phalloidin (red) and the nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL).](http://images.novusbio.com/fullsize/STAT3-Antibody-Immunohistochemistry-Paraffin-NB100-799-img0006.jpg)
![Flow Cytometry: STAT3 Antibody [NB100-799] - Flow cytometric analysis of paraformaldehyde fixed A431 cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (1 ug/mL). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/STAT3-Antibody-Flow-Cytometry-NB100-799-img0007.jpg)
![Immunohistochemistry-Paraffin: STAT3 Antibody [NB100-799] - Staining of Mouse Thymus. Antibody at 4 ug/mL. Microwaved antigen retrieval with citrate buffer pH 6, HRP-staining.](http://images.novusbio.com/fullsize/STAT3-Antibody-Immunohistochemistry-Paraffin-NB100-799-img0003.jpg)
![Immunohistochemistry-Paraffin: STAT3 Antibody [NB100-799] - Negative Control showing staining of Mouse Thymus, with no primary antibody.](http://images.novusbio.com/fullsize/STAT3-Antibody-Immunohistochemistry-Paraffin-NB100-799-img0004.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. Protein expression of Foxo1, Foxo3, and phospho-T24/32 Foxo1/3 in young (<3-month, n = 6), adult (3-18-month, n = 6), and old (18-20-month, n = 6) FVB/B6 mixed-strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean +/- SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t-test. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1111/acel.12701), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NB100-614-img0014.jpg "Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. Protein expression of Foxo1, Foxo3, and phospho-T24/32 Foxo1/3 in young (<3-month, n = 6), adult (3-18-month, n = 6), and old (18-20-month, n = 6) FVB/B6 mixed-strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean +/- SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t-test. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1111/acel.12701), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: FOXO3 Antibody [NB100-614] - Analysis of FOXO3 in human B cell lymphoma using anti-FOXO3 antibody .Image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunocytochemistry-Immunofluorescence-NB100-614-img0007.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NB100-614] - Sample: FFPE section of human ovarian carcinoma (left) and mouse renal cell carcinoma (right). Antibody: Affinity purified rabbit anti-FOXO3a used at a dilution of 1:1,000 (1ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-NB100-614-img0009.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: FOXO3 Antibody [NB100-614] - Detection of Human and Mouse FOXO3a by Western Blot. Samples: Whole cell lysate (50 ug) from HeLa, 293T, Jurkat, mouse TCMK-1, and mouse NIH3T3 cells. Antibodies: Affinity purified rabbit anti-FOXO3a antibody NB100-614 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NB100-614-img0011.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - FOXO3 Protein expression levels both control group and exercise group for skeletal muscles. Image submitted by a verified customer review *{Mouse WB}*](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NB100-614-img0012.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: FOXO3 Antibody [NB100-614] - Detection of human FOXO3a by western blot of immunoprecipitates. Samples: Whole cell lysate (1 mg for IP; 20% of IP loaded) from MCF-7 cells. Antibodies: Affinity purified rabbit anti-FOXO3a antibody NB100-614 used for IP at 6 ug/mg lysate. FOXO3a was also immunoprecipitated by rabbit anti-FOXO3a antibody NB100-613. For blotting immunoprecipitated FOXO3a, NB100-614 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunoprecipitation-NB100-614-img0013.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. Representative Western blotting results. Foxo1- or Foxo1/3-specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM-cerebellum, STR-striatum, SCD-spinal cord, CTX-cortex, BST-brain stem, MDB-midbrain, HPC-hippocampus.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Knockout-Validated-NB100-614-img0015.jpg)
![Western Blot: Rabbit Polyclonal FOXO3 Antibody [NB100-614] - Analysis of FOXO3 and FOXM1in parental HCT-116 and HCT-116-FUR cells. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-614_rabbit-polyclonal-foxo3-antibody-western-blot-1652024104015.png)
![Western Blot: FOXO3 Antibody [NB100-614] - Increased proteotoxic stress & defective autophagy in Foxo1/3/4 knockout mice. (a) Tissue lysates from 12‐month‐old WT & KO brain cortex were analyzed by WB of indicated proteins. (c) p62 IF & (d) p62 & Ub IHC on cortical neurons from 12‐month‐old WT & KO brain cortex. Red arrows point to labeling positive inclusions. Scale bar = 200 μm. (e) Quantitation of representative results for (d). (f) Indicated genotype of neural progenitor cultures was differentiated into neurons for 5 days. Some cultures were treated with rapamycin (100 ng/ml) for 24 hr on day 4 of differentiation. (h) The autophagy activity was analyzed by flow cytometry. The bar graph shows autophagy indices as % of control of (f). (i) Cultures as in (f) were treated with chloroquine (100 ng/ml) for 4 hr & analyzed for the expression levels of LC3 by WB. Representative result from three to five independent experiments is shown. (b, g, j) Quantitation of WB band densities. Only chloroquine‐treated cultures were statistically compared in (j). Error bars, mean ± SEM. *p < .05. **p < .01, ***p < .005; ****p < .001. Statistical significance was determined by one‐way ANOVA Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-310202415541916.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. (a) XY plots of FOXO1 or FOXO3 mRNA expression within the noted brain regions vs. age of the subjects at time of death. (b) Pearson correlation coefficients (r) & p‐values for the correlation of FOXO1 or FOXO3 mRNA expression in various regions of the human brain with the age. (c) The mRNA expressions of FOXO1 & FOXO3 were measured in human cerebellums (n = 33). Blue & green dots indicate samples used for WB in (d). The mRNA (e) & protein (f) expression of Foxo1, Foxo3, & phospho‐T24/32 Foxo1/3 in young (<3‐month, n = 6), adult (3‐18‐month, n = 6), & old (18–20‐month, n = 6) FVB/B6 mixed‐strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean ± SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t‐test. (g) FOXO1 IHC analysis of brain sections of WT & Foxo 1/3/4 KO mice. Residual FOXO1 immunoreactivity in KO mice is visible in endothelial cells (inset). Scale bar = 200 μm. (h) RT‐qPCR results for Foxo1 & Foxo3 mRNA. Empty bars represent WT, & colored bars represent KO tissues (n = 4). (i) Representative Western blotting results. Foxo1‐ or Foxo1/3‐specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM—cerebellum, STR—striatum, SCD—spinal cord, CTX—cortex, BST—brain stem, MDB—midbrain, HPC—hippocampus Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-310202415535143.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. (a) XY plots of FOXO1 or FOXO3 mRNA expression within the noted brain regions vs. age of the subjects at time of death. (b) Pearson correlation coefficients (r) & p‐values for the correlation of FOXO1 or FOXO3 mRNA expression in various regions of the human brain with the age. (c) The mRNA expressions of FOXO1 & FOXO3 were measured in human cerebellums (n = 33). Blue & green dots indicate samples used for WB in (d). The mRNA (e) & protein (f) expression of Foxo1, Foxo3, & phospho‐T24/32 Foxo1/3 in young (<3‐month, n = 6), adult (3‐18‐month, n = 6), & old (18–20‐month, n = 6) FVB/B6 mixed‐strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean ± SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t‐test. (g) FOXO1 IHC analysis of brain sections of WT & Foxo 1/3/4 KO mice. Residual FOXO1 immunoreactivity in KO mice is visible in endothelial cells (inset). Scale bar = 200 μm. (h) RT‐qPCR results for Foxo1 & Foxo3 mRNA. Empty bars represent WT, & colored bars represent KO tissues (n = 4). (i) Representative Western blotting results. Foxo1‐ or Foxo1/3‐specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM—cerebellum, STR—striatum, SCD—spinal cord, CTX—cortex, BST—brain stem, MDB—midbrain, HPC—hippocampus Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-3102024155456.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Increased proteotoxic stress & defective autophagy in Foxo1/3/4 knockout mice. (a) Tissue lysates from 12‐month‐old WT & KO brain cortex were analyzed by WB of indicated proteins. (c) p62 IF & (d) p62 & Ub IHC on cortical neurons from 12‐month‐old WT & KO brain cortex. Red arrows point to labeling positive inclusions. Scale bar = 200 μm. (e) Quantitation of representative results for (d). (f) Indicated genotype of neural progenitor cultures was differentiated into neurons for 5 days. Some cultures were treated with rapamycin (100 ng/ml) for 24 hr on day 4 of differentiation. (h) The autophagy activity was analyzed by flow cytometry. The bar graph shows autophagy indices as % of control of (f). (i) Cultures as in (f) were treated with chloroquine (100 ng/ml) for 4 hr & analyzed for the expression levels of LC3 by WB. Representative result from three to five independent experiments is shown. (b, g, j) Quantitation of WB band densities. Only chloroquine‐treated cultures were statistically compared in (j). Error bars, mean ± SEM. *p < .05. **p < .01, ***p < .005; ****p < .001. Statistical significance was determined by one‐way ANOVA Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-3102024155375.jpg)
![Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. (a) XY plots of FOXO1 or FOXO3 mRNA expression within the noted brain regions vs. age of the subjects at time of death. (b) Pearson correlation coefficients (r) & p‐values for the correlation of FOXO1 or FOXO3 mRNA expression in various regions of the human brain with the age. (c) The mRNA expressions of FOXO1 & FOXO3 were measured in human cerebellums (n = 33). Blue & green dots indicate samples used for WB in (d). The mRNA (e) & protein (f) expression of Foxo1, Foxo3, & phospho‐T24/32 Foxo1/3 in young (<3‐month, n = 6), adult (3‐18‐month, n = 6), & old (18–20‐month, n = 6) FVB/B6 mixed‐strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean ± SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t‐test. (g) FOXO1 IHC analysis of brain sections of WT & Foxo 1/3/4 KO mice. Residual FOXO1 immunoreactivity in KO mice is visible in endothelial cells (inset). Scale bar = 200 μm. (h) RT‐qPCR results for Foxo1 & Foxo3 mRNA. Empty bars represent WT, & colored bars represent KO tissues (n = 4). (i) Representative Western blotting results. Foxo1‐ or Foxo1/3‐specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM—cerebellum, STR—striatum, SCD—spinal cord, CTX—cortex, BST—brain stem, MDB—midbrain, HPC—hippocampus Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-614_rabbit-polyclonal-foxo3-antibody-310202415525289.jpg)